Quick answer: Vitamin D3 raises intestinal calcium absorption. Vitamin K2 as MK-7 activates matrix Gla protein and osteocalcin, the proteins that route that calcium into bone and away from soft tissue. A defensible combined product pairs 1,000 to 4,000 IU of D3 with 90 to 200 mcg of MK-7, a ratio of roughly 10:1 to 20:1 IU to micrograms. Below 90 mcg, the K2 is largely decorative.
What the label actually contains
"Vitamin D3" on a supplement label means cholecalciferol, the same molecule made in skin from 7-dehydrocholesterol under UVB. It is not ergocalciferol (D2), which is fungal and plant derived and raises serum 25(OH)D less efficiently per microgram in most comparative trials. The two are not interchangeable at the same dose.
"Vitamin K2" is a family, not a single molecule. The menaquinones are numbered by the length of their isoprenoid side chain: MK-4 has four units, MK-7 has seven, MK-8 and MK-9 longer. They differ in half-life, tissue distribution and the dose needed to move a lab marker. A label that says only "vitamin K2 45 mcg" without naming the menaquinone is telling you very little.
D3 is measured in IU or micrograms; 1 mcg of cholecalciferol equals 40 IU. K2 is measured in micrograms or, for MK-4, in milligrams. Confusing the two units is the most common arithmetic error in this category.
What the evidence shows
The mechanistic case is strong. The clinical case is uneven, and it is worth separating the two.
Bone mineral density and fracture. Vitamin D plus calcium has randomized trial support for reducing fracture risk in older adults with low intake or low serum 25(OH)D; the benefit is clearest in deficient populations and shrinks toward null in already-replete ones. For K2, the strongest randomized data come from Japanese trials using MK-4 at 45 mg per day, a pharmacological dose roughly 200 to 500 times the MK-7 doses used in Western supplements. MK-7 trials are smaller and mostly measure bone turnover markers rather than fractures.
Arterial stiffness. A three-year randomized trial in hypertensive postmenopausal women using 180 mcg MK-7 daily reported improved arterial stiffness compared with placebo. A smaller trial in healthy postmenopausal women did not reproduce the effect on the same marker. The direction is plausible; the replication is incomplete.
Vascular calcification in kidney disease. Trials in dialysis patients using MK-7 have generally not shown a clear reduction in coronary calcification progression, although some showed changes in inactive MGP levels. This is a population with disordered mineral metabolism, so results do not transfer cleanly to healthy adults.
Immune and respiratory outcomes. Vitamin D has randomized support for reducing acute respiratory infection risk, strongest in people with low baseline 25(OH)D and with daily or weekly dosing rather than large bolus doses. K2 has no comparable evidence in this area.
Dental and athletic claims. Preliminary or absent. Do not build a label claim on them.
Forms compared
| Form | Plasma half-life | Typical supplement dose | Practical notes |
|---|---|---|---|
| MK-4 | 1–2 hours | 15–45 mg, split into 2–3 daily doses | Japanese osteoporosis drug dose; requires milligram quantities, so it dominates tablet weight and cost |
| MK-7 (natto fermentation) | ~68–72 hours | 90–200 mcg once daily | Standard for combined D3+K2 products; one daily dose keeps plasma MK-7 elevated |
| MK-7 (synthetic / all-trans) | ~68–72 hours | 90–200 mcg once daily | Same menaquinone; check cis/trans ratio on the CoA, since cis isomers are less active |
| MK-8, MK-9 | Longer | Variable; not standardized | Present in fermented foods such as cheese; rarely used as isolated supplement actives |
MK-7 is the default because a single daily dose holds plasma concentration. MK-4 clears within hours, which is why the Japanese trials dosed it three times a day. A product that lists 45 mcg of "K2" as MK-4 is not equivalent to 45 mcg of MK-7; the MK-4 dose in the trial literature is a thousand times larger.
Dosage and timing
| Population or situation | D3 per day | K2 (MK-7) per day | Notes |
|---|---|---|---|
| Adult maintenance, assumed sufficient | 1,000–2,000 IU | 90–100 mcg | Matches the lower end of the 10:1 to 20:1 ratio |
| Low sun exposure, northern latitude, darker skin | 2,000–4,000 IU | 100–200 mcg | 4,000 IU is the tolerable upper intake for adults from supplements in US and EU guidance |
| Documented deficiency (under clinical care) | Higher, protocol-driven | 180–200 mcg | Requires 25(OH)D monitoring; not a self-directed dose |
| Children | 400–1,000 IU | Not routinely needed | Pediatric K2 evidence is thin; follow local pediatric guidance |
| Pregnant adults | 600 IU (US RDA) | No established RDA | Do not exceed the upper limit without clinician involvement |
Both actives are fat soluble, so take them with a meal that contains fat. A small study comparing fasting and fed intake of D3 found absorption was substantially higher with a fat-containing meal. Timing within the day matters less than consistency and the presence of dietary fat.
Safety, side effects and interactions
Vitamin K2 does not carry a published tolerable upper intake level, and trials at 180 to 360 mcg daily for up to three years have not reported a consistent safety signal. That is not the same as proof of long-term safety at any dose.
The clinically important interaction is with vitamin K antagonists. Warfarin works by inhibiting vitamin K epoxide reductase, and patients on it are managed with a stable vitamin K intake. Starting or stopping a K2 supplement changes that intake and can move INR. Anyone on warfarin, acenocoumarol or phenprocoumon should not add K2 without coordinating with their prescriber. Direct oral anticoagulants such as apixaban and rivaroxaban do not share this mechanism, but the prescribing decision still belongs to the clinician.
High-dose vitamin D without supervision is a separate concern. People with hypercalcaemia, sarcoidosis, lymphoma or other granulomatous disease can convert 25(OH)D to calcitriol outside the kidney, driving serum calcium up. They should not take high-dose D3 without monitoring. The same caution applies to anyone with a history of calcium-containing kidney stones, where the risk-benefit calculation needs a clinician.
Common side effects at typical doses are minimal. Above the 4,000 IU upper intake, the main risk is hypercalcaemia, which presents as nausea, constipation, weakness or confusion and is detected by serum calcium and 25(OH)D testing.
How to read the label
Elemental versus compound weight is the first trap. Cholecalciferol is dosed as the molecule itself, so 1,000 IU is 25 mcg of cholecalciferol, not 25 mcg of elemental vitamin D. For K2, the number on the label is the menaquinone weight, not a converted figure. There is no elemental-to-compound conversion to do, but there is a form to identify.
| Label marker | What a good label shows | What to question |
|---|---|---|
| D3 dose | In IU, with mcg in parentheses (1,000 IU = 25 mcg) | Only mcg, with no IU conversion, or a dose above 4,000 IU without a monitoring note |
| K2 identity | "Menaquinone-7 (MK-7)" with mcg amount | "Vitamin K2" with no menaquinone named, or MK-4 at a microgram dose |
| K2 dose | 90–200 mcg MK-7 | Below 90 mcg in a product marketed on the D3+K2 pairing |
| Carrier oil | MCT, olive or sunflower oil declared | No carrier declared in a softgel or oil-based capsule |
| Excipients | Short list; no titanium dioxide or azo dyes if clean label matters | Long excipient list in a low-dose product where none is needed |
| Testing | Third-party CoA available on request; heavy metals, micro, potency | No CoA, or a CoA that reports only release assay and not stability |
Ask for the stability data, not just the release assay. D3 and MK-7 both degrade under light and oxygen, and MK-7 is also sensitive to alkaline pH. A 24-month real-time stability study on the finished dosage form is the number that tells you whether the label will still be true at expiry.
Making it: what changes in production
Both actives are fat soluble, so the dosage form decision drives the rest. Softgels in an oil base are the simplest way to deliver a dissolved, bioavailable dose, and they dominate the category for that reason. Hard capsules can work if the fill is an oil or a spray-dried emulsion; a dry powder blend in a hard capsule gives noticeably lower absorption and is harder to defend.
Tablets are the difficult format. A high-dose mineral premix creates an alkaline microenvironment, and MK-7 degrades faster in that environment over shelf life. If a tablet is required, the K2 needs an overage justified by stability data, and the formulator should expect to test at 0, 3, 6, 12, 18 and 24 months rather than relying on a single release assay. Effervescent tablets are a poor fit for both actives because of the moisture and pH environment during dissolution and storage.
Gummies are feasible but constrained. The thermal process and the water activity of a gummy are hostile to both D3 and MK-7, so overage is higher and flavour masking becomes part of the formulation brief. Stick packs and sachets can carry an oil-based powder, but the fat content per sachet has to be enough to support absorption. Liquid drops work well for D3 and are harder for MK-7 because of light sensitivity and the need for a solubilized oil phase.
At ZOOMSHEAL, the in-house dosage forms are hard capsules, softgels, tablets, gummies, powder in jars, sachets and stick packs, liquid drops and effervescent tablets. A pilot run typically starts at 500 units per SKU (1,000 for capsules, tablets and softgels); softgels can start at 1,000 to 2,000 pieces for a pilot, while gummies and stick packs need higher first runs because of the setup cost. Lead time is 4 to 6 weeks after formula and artwork approval, with sampling in 7 to 10 days. Every batch ships with a CoA, and third-party testing for heavy metals, microbiology and potency is available on request.
Buying checklist for brands
- Decide the ratio before the dose. A 2,000 IU D3 with 100 mcg MK-7 product sits at 20:1 and is easy to defend; a 5,000 IU D3 with 45 mcg MK-7 sits at 111:1 and is effectively a D3 product.
- Specify MK-7, not "K2," and ask for the cis/trans ratio on the CoA. All-trans MK-7 is the active form.
- Choose the dosage form against the stability data, not against the marketing deck. Softgel first; hard capsule with an oil fill second; tablet only with a documented overage and 24-month data.
- Ask for a real-time stability protocol, not an accelerated study alone, for both actives.
- Confirm the carrier oil and check that the fat content per unit is enough to support absorption.
- Check the certificate scope. GMP, ISO 9001, ISO 22000 and HACCP are baseline; Halal is line- and product-specific, so confirm the line.
- Remember that FDA facility registration is not FDA approval. Dietary supplements have no pre-market approval in the US, and any supplier implying otherwise is a poor signal.
Frequently asked questions
Can I take vitamin D3 without vitamin K2?
Yes. Most vitamin D guidelines do not require K2, and the pairing is an optimization argument rather than a safety requirement. The case for adding K2 is strongest when D3 is used at the upper end of the range, around 4,000 IU daily, over long periods, and when dietary menaquinone intake is low. At 1,000 IU, the routing argument is thinner.
What is the right D3 to K2 ratio?
There is no regulatory ratio. The practical range used by formulators is 10:1 to 20:1 IU of D3 to micrograms of MK-7, which puts 2,000 IU with 100 to 200 mcg. Below 90 mcg of MK-7, the K2 is unlikely to move the markers that matter. Above 200 mcg, the incremental evidence is limited.
Does K2 need to be taken with fat?
Yes. MK-7 is fat soluble, and absorption improves when it is taken with a meal containing fat. A softgel in an oil base partly solves this by delivering the actives already in a lipid phase, but a fat-containing meal still helps. Taking it on an empty stomach is the least efficient option.
Is natto-derived MK-7 suitable for vegans?
The MK-7 itself is plant-based when produced by natto fermentation. The capsule shell is the usual problem: many softgels and hard capsules use gelatin. Look for a starch, HPMC or pullulan shell if the vegan claim matters, and check the carrier oil, since some are not vegan.
How long does it take for 25(OH)D to rise?
With consistent daily dosing, serum 25(OH)D typically reaches a new steady state in about eight to twelve weeks. Testing before and after is the only way to dose accurately, because the response varies with baseline, body weight, skin tone and sun exposure. A single test after two weeks tells you very little.
Can I take D3 and K2 with warfarin?
Not without coordinating with your prescriber. Warfarin works by interfering with vitamin K recycling, and patients are managed with a stable vitamin K intake. Adding K2 changes that intake and can move INR. This is a clinically significant interaction, not a theoretical one, and the decision belongs to the clinician managing the anticoagulation.
References
- National Institutes of Health, Office of Dietary Supplements. Vitamin D Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
- National Institutes of Health, Office of Dietary Supplements. Vitamin K Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/VitaminK-HealthProfessional/
- European Food Safety Authority. Scientific Opinion on the Tolerable Upper Intake Level of Vitamin D. EFSA Journal. https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2012.2813
- European Food Safety Authority. Scientific Opinion on Dietary Reference Values for Vitamin K. EFSA Journal. https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2017.4780
- PubMed search: menaquinone-7 arterial stiffness randomized trial. https://pubmed.ncbi.nlm.nih.gov/?term=menaquinone-7+arterial+stiffness+randomized
- PubMed search: vitamin K2 osteocalcin carboxylation bone. https://pubmed.ncbi.nlm.nih.gov/?term=vitamin+K2+osteocalcin+carboxylation+bone
- PubMed search: vitamin D respiratory infection randomized trial. https://pubmed.ncbi.nlm.nih.gov/?term=vitamin+D+respiratory+infection+randomized+trial
- US Food and Drug Administration. Dietary Supplements: Guidance and Regulatory Information. https://www.fda.gov/food/dietary-supplements
Reviewed by Dr. Xu Wei, PhD, formulation scientist at ZOOMSHEAL in Guangzhou (23 years of supplement contract manufacturing). Last updated: November 2026. This article is for education and does not replace medical advice.






